Engineering Papers⌕ Search

SEARCH · Engineering Papers

Results for “THORIUM 225”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 records

Nuclear Data Sheets for A = 225

The evaluators present in this publication spectroscopic data and level schemes from radioactive decay and nuclear reactions for all isobars with mass number A = 225.

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗

The application of poorly crystalline silicotitanate in production of 225 Ac

Actinium-225 ( 225 Ac) can be produced from a Thorium-229/Radium-225 ( 229 Th/ 225 Ra) generator, from high/low energy proton irradiated natural Thorium or Radium-226 target. Titanium based ion exchanger were evaluated for purification of 225 Ac. Poorly crystalline silicotitanate (PCST) ion exchanger had high selectivity for Ba, Ag and Th. 225 Ac was received with trace amounts of 227 Ac, 227 Th and 223 Ra, and the solution was used to evaluate the retention of the isotopes on PCST ion exchanger. Over 90% of the 225 Ac was recovered from PCST, and the radiopurity was >99% (calculated based on 225 Ac, 227 Th, and 223 Ra). The capacity of the PCST inorganic ion exchange for Barium and 232 Th was determined to be 24.19 mg/mL for Barium and 5.05 mg/mL for Thorium. PCST ion exchanger could separate 225 Ac from isotopes of Ra and Th, and the process represents an interesting one step separation that could be used in an 225 Ac generator from 225 Ra and/or 229 Th. Capacity studies indicated PCST could be used to separate 225 Ac produced on small 226 Ra targets (0.3–1 g), but PCST did not have a high enough capacity for production scale Th targets (50–100 g).

43 PARTICLE ACCELERATORS↗

Simultaneous Separation of Actinium and Radium Isotopes from a Proton Irradiated Thorium Matrix

A new method has been developed for the isolation of 223,224,225 Ra, in high yield and purity, from a proton irradiated 232 Th matrix. We report an all-aqueous process using multiple solid-supported adsorption steps including a citrate chelation method developed to remove >99.9% of the barium contaminants by activity from the final radium product. Moreover, we developed a procedure involving the use of three columns in succession, and the separation of 223,224,225 Ra from the thorium matrix was obtained with an overall recovery yield of 91 ± 3%, average radiochemical purity of 99.9%, and production yields that correspond to physical yields based on previously measured excitation functions.

38 RADIATION CHEMISTRY, RADIOCHEMISTRY, AND NUCLEA↗

Extraction chromatography of 225 Ac and lanthanides on N,N-dioctyldiglycolamic acid /1-butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide solvent impregnated resin

The alpha-emitter 225 Ac (t 1/2 = 9.92 d) is currently under development for targeted alpha-particle therapy of cancer, and accelerator production of 225 Ac via proton irradiation of thorium targets requires robust separations of 225 Ac from chemically similar fission product lanthanides. Additionally, the lanthanide elements represent critical components in modern technologies, and radiolanthanides such as 140 Nd (t 1/2 = 3.37 d) also have potential application in the field of nuclear medicine. The ionic liquid, 1-butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide ([Bmim][NTf 2 ]), combined with the diglycolamide extractant, N,N-dioctyldiglycolamic acid (DODGAA), was adsorbed on macroporous resin support to produce a solvent impregnated resin (SIR) that was investigated for separations of 225 Ac and lanthanides. The equilibrium distribution coefficients (Kd) of the rare earth elements (Sc(III), Y(III), Ln(III)), 225 Ac(III), Th(IV), and U(VI) on the prepared DODGAA/[Bmim][NTf 2 ]-SIR were determined from batch adsorption experiments in HCl and HNO 3 media. The DODGAA/[Bmim][NTf2]-SIR exhibited preferential uptake of the heavier lanthanide elements while allowing for the separation of the lighter lanthanides. Column separations utilizing the DODGAA/[Bmim][NTf 2 ]-SIR were effective at separating the lighter lanthanides from each other, and separating 225 Ac from a mixture of lanthanides, 213 Bi, and 225 Ra without the need for additional complexing agents.

37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CH↗

Radiometric evaluation of diglycolamide resins for the chromatographic separation of actinium from fission product lanthanides

Actinium-225 is a potential Targeted Alpha Therapy (TAT) isotope. It can be generated with high energy (≥ 100 MeV) proton irradiation of thorium targets. The main challenge in the chemical recovery of 225 Ac lies in the separation from thorium and many fission by-products most importantly radiolanthanides. We recently developed a separation strategy based on a combination of cation exchange and extraction chromatography to isolate and purify 225 Ac. In this study, actinium and lanthanide equilibrium distribution coefficients and column elution behavior for both TODGA (N,N,N',N'-tetra- n -octyldiglycolamide) and TEHDGA (N,N,N',N'-tetrakis-2-ethylhexyldiglycolamide) were determined. Density functional theory (DFT) calculations were performed and were in agreement with experimental observations providing the foundation for understanding of the selectivity for Ac and lanthanides on different DGA (diglycolamide) based resins. The results of Gibbs energy (ΔG aq ) calculations confirm significantly higher selectivity of DGA based resins for Ln III over Ac III in the presence of nitrate. As a result, DFT calculations and experimental results reveal that Ac chemistry cannot be predicted from lanthanide behavior under comparable circumstances.

225Ac↗

Recommended Nuclear Data for the Production of Selected Therapeutic Radionuclides

Increasing interest in the treatment of human disease by means of targeted radionuclide-based therapies requires an accurate understanding of achievable yields and quantification of realisable degrees of purity. Important studies within a more extensive Coordinated Research Project of the International Atomic Energy Agency (IAEA CRP) have included in-depth assessments and evaluations of all available measured cross-section data for ten nuclear reactions leading to the formation of 131 Cs, 131 Ba, 225 Ac, 225 Ra, 227 Th, 227 Ac, 230 U and 230 Pa for various on-going and proposed therapeutic applications in nuclear medicine. Equivalent studies were also undertaken of possible reactions to produce the 178W /low-spin 178m Ta generator system that has been clinically applied in diagnosis by means of SPECT - these particular cross-section studies and recommendations are included in this paper for completeness. All available measured data have been critically reviewed and assessed to produce statistically consistent datasets. Selected datasets have been fitted by a least-squares method with Padé approximations of variable order to evaluate the production cross sections and corresponding uncertainties. New measurements have been made in some instances, and reported data have been adjusted to accommodate new nuclear decay or monitor reaction data which altered the original reported quantities adversely. Insufficient measured data are available in many cases to permit a reliable evaluation of cross sections, and these instances are discussed. Finally, recommended therapeutic radionuclide production reaction data and their uncertainties are available on the Web page of the IAEA Nuclear Data Section at www-nds.iaea.org/radionuclides/ and also at the IAEA medical portal www-nds.iaea.org/medportal/.

63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTAN↗

Large scale accelerator production of 225Ac: Effective cross sections for 78–192 MeV protons incident on 232Th targets

Actinium-225 and 213 Bi have been used successfully in targeted alpha therapy (TAT) in preclinical and clinical research. This paper is a continuation of research activities aiming to expand the availability of 225 Ac. The high energy proton spallation reaction on natural thorium metal target has been utilized to produce millicurie quantities of 225 Ac. The results of sixteen irradiation experiments of Th metal at beam energies between 78 and 200 MeV are summarized in this work. Irradiations have been conducted at Brookhaven National Laboratory (BNL) and Los Alamos National Laboratory (LANL), while target dissolution and processing was carried out at Oak Ridge National Laboratory (ORNL). Excitation functions for actinium and thorium isotopes as well as for some of the fission products are presented. The cross sections for production of 225 Ac range from 3.6 to 16.7 mb in the incident proton energy range of 78 to 192 MeV. Based on these data, production of Curie quantities of 225Ac is possible by irradiating a 5.0 g cm -2232 Th target for 10 days in either BNL or LANL proton irradiation facilities.

139Ce↗

Accelerator Production of {sup 225}Ac For Alpha-Immunotherapy

{sup 225}Ac has tremendous potential for the treatment of metastatic cancer due to the four alpha-particles emitted during its decay to stable {sup 209}Bi. Additionally, it is one of the few alpha-emitters being considered for clinical trials. The anticipated {sup 225}Ac demand for these trials is expected to far exceed the annual worldwide supply of approximately 1,000 mCi/yr. Consequently, the DOE Office of Science has funded investigations into accelerator-based production of {sup 225}Ac. Existing {sup 232}Th(p,x){sup 225}Ac cross section data indicate that up to 480 mCi/day of {sup 225}Ac could be created by bombarding a thick target of natural thorium with 100 MeV protons at the Los Alamos Isotope Production Facility. To verify these predictions, experiments are underway at the Los Alamos Neutron Science Center to measure the {sup 232}Th(p,x){sup 225}Ac production cross sections for protons in the energy range 40-200 MeV, and at 800 MeV. For 800 MeV protons, preliminary results indicate that the {sup 225}Ac production cross section is 12.4{+-}0.6 mb and the {sup 225}Ra production cross section is 3.2{+-}0.2 mb. Moreover, preliminary results suggest that the {sup 227}Ac production cross section is 16{+-}1 mb. Experiments to measure these same cross sections at proton energies below 200 MeV are planned for the last half of calendar year 2010.

43 PARTICLE ACCELERATORS↗

Chromatographic separation of the theranostic radionuclide 111 Ag from a proton irradiated thorium matrix

Column chromatographic methods have been developed to separate no-carrier-added 111 Ag from proton irradiated thorium targets and associated fission products as an ancillary process to an existing 225 Ac separation design. In this paper, we report the separation of 111 Ag both prior and subsequent to 225 Ac recovery using CL resin, a solvent impregnated resin (SIR) that carries an organic solution of alkyl phosphine sulfides (R 3 P = S) and alkyl phosphine oxides (R 3 P = O). The recovery yield of 111 Ag was 93 ± 9% with a radiochemical purity of 99.9% (prior) and 87 ± 9% with a radiochemical purity of 99.9% (subsequent to) 225 Ac recovery. Both processes were successfully performed with insignificant impacts on 225 Ac yields or quality. Measured equilibrium distribution coefficients for silver and ruthenium (a residual contaminant) on CL resin in hydrochloric and nitric acid media are reported, to the best of our knowledge, for the first time. Finally and additionally, measured cross sections for the production of 111 Ag and 110m Ag for the 232 Th(p,f) 110m,111 Ag reactions are reported within.

111Ag↗

Measurement of cross sections for the {sup 232}Th(P,4n){sup 229}Pa reaction at low proton energies

The alpha-emitters {sup 225}Ac and {sup 213}Bi are of great interest for alpha-radioimmunotherapy which uses radioisotopes attached to cancer-seeking antibodies to efficiently treat various types of cancers. Both radioisotopes are daughters of the long-lived {sup 229}Th(t{sub 1/2} = 7880y). {sup 229}Th can be produced by proton irradiation of {sup 232}Th and {sup 230}Th, either directly or through production of isobars that beta-decay into {sup 229}Th. To obtain excitation functions, {sup 232}Th and {sup 230}Th have been irradiated at the On-Line Test Facility at the Holifield Radioactive Ion Beam Facility at ORNL. Benchmark tests conducted with Cu and Ni foils show very good agreement with literature results. The experiments with thorium targets were focused on the production of {sup 229}Pa and its daughter {sup 225}Ac from both {sup 232}Th and {sup 230}Th. Differential cross-sections for production of {sup 229}Pa and other Pa isotopes have been obtained.

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗

An experimental study of the solubility and speciation of thorium in chloride-bearing aqueous solutions at temperatures up to 250 °C

In this study, the solubility and speciation of Th in Cl-bearing solutions saturated in ThO2 was investigated experimentally at 150, 175, 200, 225 and 250°C, and saturated water vapor pressure. At these experimental conditions (pH 25°C < 3.8, mNaCl < 2.5), Th-chloride complexation is insignificant, and the solubility of Th is controlled by hydrolysis. The two main species in solution were identified as Th(OH) 2 2+ and Th(OH) 4 ° and formed via the reactions Th 4+ + 2OH - ↔ Th(OH)$2+\atop{2}$ and Th 4+ + 4OH - ↔ Th(OH)$0\atop{4}$. The logarithms of the formation constants determined for the first reaction are 23.91 ± 0.05, 24.79 ± 0.07, 25.78 ± 0.05, and 25.85 ± 0.05 for 175, 200, 225 and 250°C, respectively, and 42.18 ± 0.06, 43.50 ± 0.07, 43.17 ± 0.08, and 43.74 ± 0.11 for the second reaction at the same temperatures. Formation constants could not be determined reliably for 150 °C. Extrapolations of our formation constants to 25°C are in excellent agreement with the values determined at 25 °C by Neck and Kim (2001) and Ekberg et al. (2000). Finally, for natural systems buffered by thorianite (ThO 2 ), the solubility determined in our study likely reflects a minimum, as the presence of additional ligands would lead to higher solubility.

37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CH↗

Application of ion exchange and extraction chromatography to the separation of actinium from proton-irradiated thorium metal for analytical purposes

We present that actinium-225 (t 1/2 = 9.92 d) is an α-emitting radionuclide with nuclear properties well-suited for use in targeted alpha therapy (TAT), a powerful treatment method for malignant tumors. Actinium-225 can also be utilized as a generator for 213 Bi (t 1/2 45.6 min), which is another valuable candidate for TAT. Actinium-225 can be produced via proton irradiation of thorium metal; however, long-lived 227 Ac (t 1/2 = 21.8 a, 99% β - , 1% α) is co-produced during this process and will impact the quality of the final product. Thus, accurate assays are needed to determine the 225 Ac/ 227 Ac ratio, which is dependent on beam energy, irradiation time and target design. Accurate actinium assays, in turn, require efficient separation of actinium isotopes from both the Th matrix and highly radioactive activation by-products, especially radiolanthanides formed from proton-induced fission. In this study, we introduce a novel, selective chromatographic technique for the recovery and purification of actinium isotopes from irradiated Th matrices. A two-step sequence of cation exchange and extraction chromatography was implemented. Radiolanthanides were quantitatively removed from Ac, and no non-Ac radionuclidic impurities were detected in the final Ac fraction. An 225 Ac spike added prior to separation was recovered at ≥98%, and Ac decontamination from Th was found to be ≥10 6 . Finally, the purified actinium fraction allowed for highly accurate 227 Ac determination at analytical scales, i.e., at 227 Ac activities of 1–100 kBq (27 nCi to 2.7 μCi).

38 RADIATION CHEMISTRY, RADIOCHEMISTRY, AND NUCLEA↗

Engineered Recognition of Tetravalent Zirconium and Thorium by Chelator–Protein Systems: Toward Flexible Radiotherapy and Imaging Platforms

Targeted α therapy holds tremendous potential as a cancer treatment: it offers the possibility of delivering a highly cytotoxic dose to targeted cells while minimizing damage to surrounding healthy tissue. The metallic α-generating radioisotopes 225 Ac and 227 Th are promising radionuclides for therapeutic use, provided adequate chelation and targeting. In this work, we demonstrate a new chelating platform composed of a multidentate high-affinity oxygen-donating ligand 3,4,3-LI(CAM) bound to the mammalian protein siderocalin. Respective stability constants log β 110 = 29.65 ± 0.65, 57.26 ± 0.20, and 47.71 ± 0.08, determined for the Eu III (a lanthanide surrogate for Ac III ), Zr IV , and Th IV complexes of 3,4,3-LI(CAM) through spectrophotometric titrations, reveal this ligand to be one of the most powerful chelators for both trivalent and tetravalent metal ions at physiological pH. The resulting metal-ligand complexes are also recognized with extremely high affinity by the siderophore-binding protein siderocalin, with dissociation constants below 40 nM and tight electrostatic interactions, as evidenced by X-ray structures of the protein:ligand:metal adducts with Zr IV and Th IV . Finally, differences in biodistribution profiles between free and siderocalin-bound 238 Pu IV -3,4,3-LI(CAM) complexes confirm in vivo stability of the protein construct. The siderocalin:3,4,3-LI(CAM) assembly can therefore serve as a "lock" to consolidate binding to the therapeutic 225 Ac and 227 Th isotopes or to the positron emission tomography emitter 89 Zr, independent of metal valence state.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Production of Actinium-225 via High Energy Proton Induced Spallation of Thorium-232

The science of cancer research is currently expanding its use of alpha particle emitting radioisotopes. Coupled with the discovery and proliferation of molecular species that seek out and attach to tumors, new therapy and diagnostics are being developed to enhance the treatment of cancer and other diseases. This latest technology is commonly referred to as Alpha Immunotherapy (AIT). Actinium-225/Bismuth-213 is a parent/daughter alpha-emitting radioisotope pair that is highly sought after because of the potential for treating numerous diseases and its ability to be chemically compatible with many known and widely used carrier molecules (such as monoclonal antibodies and proteins/peptides). Unfortunately, the worldwide supply of actinium-225 is limited to about 1,000mCi annually and most of that is currently spoken for, thus limiting the ability of this radioisotope pair to enter into research and subsequently clinical trials. The route proposed herein utilizes high energy protons to produce actinium-225 via spallation of a thorium-232 target. As part of previous R and D efforts carried out at Argonne National Laboratory recently in support of the proposed US FRIB facility, it was shown that a very effective production mechanism for actinium-225 is spallation of thorium-232 by high energy proton beams. The base-line simulation for the production rate of actinium-225 by this reaction mechanism is 8E12 atoms per second at 200 MeV proton beam energy with 50 g/cm2 thorium target and 100 kW beam power. An irradiation of one actinium-225 half-life (10 days) produces {approx}100 Ci of actinium-225. For a given beam current the reaction cross section increases slightly with energy to about 400 MeV and then decreases slightly for beam energies in the several GeV regime. The object of this effort is to refine the simulations at proton beam energies of 400 MeV and above up to about 8 GeV. Once completed, the simulations will be experimentally verified using 400 MeV and 8 GeV protons available at Fermi National Accelerator Laboratory. Targets will be processed at Argonne National Laboratory to separate and purify the actinium-225 that will subsequently be transferred to NorthStar laboratory facilities for product quality testing and comparison to the product quality of ORNL produced actinium-225, which is currently the industry standard. The test irradiations at FNAL will produce 1-20 mCi per day which is more than sufficient for quantitative evaluation of the proposed production process. The beneficial outcome of this effort will be a new production route for actinium-225 that does not use or require any uranium-233 materials owned by DOE or use any radium-226 as an irradiation target but can supply the medical community's needs for actinium-225 now and in the future.

07 ISOTOPE AND RADIATION SOURCES↗

Production of Th 229 for medical applications: Excitation functions of low-energy protons on Th 232 targets

As a part of a general program to evaluate production routes for 229 Th, we studied production of 229 Th via proton-induced reactions on 232 Th targets bombarded with low-energy protons, E p ≤ 40MeV. The reported excitation functions include those for proton-induced reactions on natural thorium yielding to 228,229,230&232 Pa isotopes; 232 Th( p,xn ) reactions, where x=1, 3, 4, and 5, at proton energy ranges of 12–40 MeV. Although the data for 232 Th(p,n) 228 Pa, 232 Th(p,3n) 230 Pa, and 232 Th(p,5n) 232 Pa reactions were deduced by direct analysis of the thorium foils after irradiation, the data for 232 Th(p,4n) 229 Pa were obtained by radiochemical techniques. The half-life of 229 Pa was evaluated and determined to be 1.55 ± 0.01 d. Further, the α-branching ratio, α/(α + EC) of 229 Pa was evaluated to be 0.53 ± 0.10% by allowing 229 Pa to decay for ~7d, then chemically extracting and quantifying the 225 Ac (t 1/2 = 10.0±0.1d) from 229 Pa samples. In addition, we report the effective production cross section of 229 Th in a thick 232 Th target in the proton energy range of 23–33 MeV. The peak of the excitation function for the 232 Th(p,4n) 229 Pa reaction occurs at 162 ± 14 mb and E p =29.7±0.5MeV. This is only slightly larger than the effective cross section for the 232 Th(p,x) 229 Th reaction (obtained from a thick target experiment). This data indicates that the 232 Th(p,4n) 229 Pa reaction is the major reaction pathway for the cumulative 232 Th(p,x) 229 Th reaction cross section in this energy range. The measured cross sections were compared with theoretical cross sections using the simulation codes Particle and Heavy Ion Transport code System (PHITS) and Monte Carlo Neutral Particle 6 (MCNP6). Furthermore, at proton energy ranges of 12–33 MeV, the cumulative excitation function predicted by PHITS for the reactions leading to 229 Th was in close agreement with the experimental function, whereas the function predicted by MCNP6 was a factor of two higher at the peak of the excitation function.

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗

The solubility of thorium in carbonate-bearing solutions at hydrothermal conditions

Thorium mineralization is frequently hosted in carbonate-bearing rocks, and thorium commonly substitutes into the structures of carbonate-bearing minerals that have precipitated from or been modified by hydrothermal fluids. Given this common association, it is reasonable to consider the hypothesis that the presence of carbonate ligands in hydrothermal solutions promotes the transport of Th through the formation of stable aqueous complexes. Our ability to evaluate this hypothesis, however, is hindered by the lack of experimental data for Th-carbonate species at conditions beyond ambient. The low-temperature data indicate that carbonate is a strong complexing agent for Th. In this contribution, we investigate the solubility of Th in carbonate-bearing fluids relevant to natural systems (0.05–0.5 m NaHCO 3 /Na 2 CO 3 ; pH T ~ 7.8–9.8) at elevated temperature (175–250 °C). We demonstrate that, in contrast to the behavior of Th at low temperature, the stability of Th-carbonate complexes is not sufficient for them to predominate at these conditions. Instead, the solubility of Th is governed by hydrolysis reactions. Under the experimental conditions investigated, the predominant hydroxyl complexes are Th(OH) 4 0 and Th(OH) 5 -. Furthermore, thermodynamic formation constants were derived for these species at the temperatures considered in our experiments (log β 4 = 43.34 and 44.31 at 175 and 200 °C, respectively, and log β 5 = 46.15 and 47.9 at 225 and 250 °C, respectively) to permit forward modeling of Th mobility in natural systems. Our study indicates that carbonate ions are unlikely to play a role in transporting Th in hydrothermal fluids. Summarizing the results of this study and our previous studies of the solubility of Th in hydrothermal fluids, we conclude that SO 4 2- is the primary ligand responsible for the hydrothermal transport of Th.

37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CH↗

Gadolinium vanadate nanocrystals as carriers of α-emitters ( 225 Ac, 227 Th) and contrast agents

Gadolinium vanadate (GdVO 4 ) core and core +2 shell nanocrystals (NCs) were evaluated for in vitro retention of 225 Ac, 227 Th, and their first decay daughters, 221 Fr and 223 Ra, respectively. GdVO 4 NCs with a tetragonal crystal system (zircon-type) and spherical morphology were obtained by precipitation of GdCl 3 and Na 3 VO 4 using sodium citrate as a complexing agent. The growth of two nonradioactive GdVO 4 shells on both Gd( 225 Ac)VO 4 and Gd( 227 Th)VO 4 core NCs was demonstrated by an increase of 0.7 nm and 2 nm in the crystallite size, respectively. The maximum leakage of 225 Ac was 15% and 2.4% from core and core + 2 shells, whereas the leakage of 227 Th was 3% and 1.5%, respectively. The presence of two nonradioactive GdVO 4 shells increased the retention of 221 Fr and 223 Ra by 20% and 15% with respect to core NCs. Furthermore, a longitudinal proton relaxivity, r 1 = 0.9289 s –1 mM –1 , confirmed their potential application as contrast agents for magnetic resonance imaging. In summary, GdVO 4 NCs show promising capabilities as radionuclide carriers with partial retention of decay daughters and as contrast agents for theranostic applications.

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗